Drugs / TAF
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT04551261 | Jan → Mar 2021 | chronic hepatitis B virus infection | Sunshine Lake Pharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TAF | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04551261 ↗ |
| Action | Inhibit | “It is a hepatitis B virus (HBV) nucleoside analog reverse transcriptase inhibitor and is indicated for the treatment of chronic hepatitis B virus infection in adults with...” NCT04551261 ↗ |